# Genomic Technology Core

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2022 · $165,250

## Abstract

PROJECT SUMMARY/ABSTRACT – Genomic Technology Core
The latest, cutting-edge genomic technologies including bulk and single-cell profiling of the transcriptome (e.g.
RNA-seq), epigenome (e.g. ATAC-seq) and proteome (e.g. CITE-seq), represent powerful new tools for the
advancement of precision medicine research, particularly when used to analyze biospecimens from well
clinically-phenotyped individuals. These rapidly evolving technologies, with their requirements for specialized
sample preparation and storage, genomic expertise and informatics skills, present a challenge for many clinical
and translational researchers in rheumatology, a field where the need for better molecular characterization and
improved delineation of disease subtypes is also a tremendous need. The goal of the Genomic Technology (GT)
Core is to provide autoimmune rheumatic disease investigators turn-key solutions to cutting-edge genomic
assays. To achieve this goal, we propose the following Aims: 1) Develop novel genomic assays and tailor them
for direct application to the investigation of rheumatic disease patients. The GT Core will leverage the innovative
expertise of the Ye Lab to develop multimodal, single-cell sequencing assays, high-throughput single cell
proteomic assays, and spatial single-cell transcriptomic approaches. 2) Provide genomic consultation services
and at-scale services for bulk and single-cell sequencing assays. The GT Core will draw on the collaborative
genomic resource lab, the Genomics CoLab (Led by co-director Dr. Eckalbar), to develop workflows and analytic
pathways geared toward the study of autoimmune disease that can be used by rheumatic disease investigators
following consultation on genomic assay choice and study design, enabling them to implement cutting-edge
genomic technologies for their projects. 3) Integrate and oversee the centralized biospecimen collection, storage
and project tracking systems that are available, to ensure optimal use of patient samples and the integration and
sharing of data between projects. The GT Core will continue to monitor the rigor and reproducibility of complex
experimental pathways to also ensure the quality of the experimental data. The GT Core will closely collaborate
with the Clinical Data Informatics (CDI) cores, to develop project specific sample tracking and metdata storage
systems through Research Electronic Data Capture (REDCap) to ensure appropriate linkage of clinical data with
biospecimen results. The GT Core will work closely with the IB Core to ensure that genomic data streams can
be easily integrated into analysis workflows. The GT Core provides a robust framework for the application of
novel, cutting-edge genomic technologies and will enable rheumatology investigators to maximally utilize all the
tools available for the advancement of precision medicine research in rheumatology.

## Key facts

- **NIH application ID:** 10469677
- **Project number:** 5P30AR070155-07
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Chun Jimmie Ye
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $165,250
- **Award type:** 5
- **Project period:** 2016-09-21 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10469677

## Citation

> US National Institutes of Health, RePORTER application 10469677, Genomic Technology Core (5P30AR070155-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10469677. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*